Independent Portfolio Consultants Inc. Boosts Stake in Shire PLC (NASDAQ:SHPG)

Independent Portfolio Consultants Inc. raised its stake in shares of Shire PLC (NASDAQ:SHPG) by 27.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,626 shares of the biopharmaceutical company’s stock after buying an additional 354 shares during the period. Independent Portfolio Consultants Inc.’s holdings in Shire PLC were worth $269,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of SHPG. Russell Investments Group Ltd. acquired a new stake in Shire PLC during the fourth quarter valued at approximately $505,000. Vident Investment Advisory LLC acquired a new stake in Shire PLC during the fourth quarter valued at approximately $340,000. Israel Discount Bank of New York GFN acquired a new stake in Shire PLC during the fourth quarter valued at approximately $559,000. Teachers Advisors LLC raised its stake in Shire PLC by 24.6% in the fourth quarter. Teachers Advisors LLC now owns 250,804 shares of the biopharmaceutical company’s stock valued at $42,732,000 after buying an additional 49,443 shares during the last quarter. Finally, Macquarie Group Ltd. raised its stake in Shire PLC by 2.2% in the fourth quarter. Macquarie Group Ltd. now owns 1,417 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 31 shares during the last quarter. 20.93% of the stock is currently owned by institutional investors.

Shares of Shire PLC (NASDAQ:SHPG) opened at 167.46 on Monday. Shire PLC has a one year low of $161.09 and a one year high of $209.22.

Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share for the quarter, beating analysts’ consensus estimates of $3.22 by $0.41. The business had revenue of $3.57 billion during the quarter. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. The business’s quarterly revenue was up 109.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.12 EPS. On average, equities analysts predict that Shire PLC will post $14.89 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Independent Portfolio Consultants Inc. Boosts Stake in Shire PLC (NASDAQ:SHPG)” was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.wkrb13.com/markets/2285251/independent-portfolio-consultants-inc-boosts-stake-in-shire-plc-nasdaqshpg.html.

SHPG has been the topic of several recent research reports. Royal Bank of Canada reaffirmed a “buy” rating and issued a $221.00 price target on shares of Shire PLC in a report on Tuesday, March 14th. Jefferies Group LLC set a $239.00 price target on shares of Shire PLC and gave the company a “buy” rating in a report on Saturday, March 18th. Goldman Sachs Group, Inc. (The) reissued a “focus list” rating on shares of Shire PLC in a research note on Tuesday, March 21st. HSBC Holdings plc lowered shares of Shire PLC from a “hold” rating to a “reduce” rating in a research note on Friday, May 19th. Finally, Sanford C. Bernstein lowered shares of Shire PLC from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $209.22 to $161.09 in a research note on Thursday, May 25th. One analyst has rated the stock with a sell rating, six have issued a hold rating and seventeen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $223.01.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285251/independent-portfolio-consultants-inc-boosts-stake-in-shire-plc-nasdaqshpg.html

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.